{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:48:58Z","timestamp":1776376138234,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13011-016-0048-3","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:25:18Z","timestamp":1452731118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey"],"prefix":"10.1186","volume":"11","author":[{"given":"Alissa M.","family":"Greer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Amlani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Moreheart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane A.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,14]]},"reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/J354v16n01_04","volume":"16","author":"C Layson-Wolf","year":"2002","unstructured":"Layson-Wolf C, Goode J-V, Small RE. Clinical use of methadone. J Pain Palliat Care Pharmacother. 2002;16:29\u201359.","journal-title":"J Pain Palliat Care Pharmacother."},{"key":"48_CR2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1360-0443.2006.01714.x","volume":"102","author":"a Fugelstad","year":"2007","unstructured":"Fugelstad a, Stenbacka M, Leifman a, Nylander M, Thiblin I. Methadone maintenance treatment: The balance between life-saving treatment and fatal poisonings. Addiction. 2007;102:406\u201312.","journal-title":"Addiction"},{"key":"48_CR3","volume":"8","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev Online. 2009;8;CD002209.","journal-title":"Cochrane Database Syst Rev Online."},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.03.002","volume":"151","author":"Z Marshall","year":"2015","unstructured":"Marshall Z, Dechman MK, Minichiello A, Alcock L, Harris GE. Peering into the literature: A systematic review of the roles of people who inject drugs in harm reduction initiatives. Drug Alcohol Depend. 2015;151:1\u201314.","journal-title":"Drug Alcohol Depend."},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","volume":"93","author":"L a Marsch","year":"1998","unstructured":"Marsch L a. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addict Abingdon Engl. 1998;93:515\u201332.","journal-title":"Addict Abingdon Engl"},{"key":"48_CR6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10461-013-0584-z","volume":"18","author":"H Reddon","year":"2014","unstructured":"Reddon H, Milloy MJ. Simo a., Montaner J, Wood E, Kerr T. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users. AIDS Behav. 2014;18:740\u20136.","journal-title":"AIDS Behav"},{"key":"48_CR7","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.drugpo.2012.10.003","volume":"24","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Methadone diversion as a protective strategy: The harm reduction potential of \u201cgenerous constraints.\u201d. Int J Drug Policy. 2013;24:e43\u201350.","journal-title":"Int J Drug Policy."},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF03403970","volume":"101","author":"J Buxton","year":"2010","unstructured":"Buxton J. a., Kuo ME, Ramji S, Yu A, Krajden M. Methadone use in relation to hepatitis C virus testing in British Columbia. Can J Public Health. 2010;101:491\u20134.","journal-title":"Can J Public Health."},{"key":"48_CR9","unstructured":"Methadone Maintenance Program: Clinical Practice Guidelines. College of Physicians and Surgeons. 2014. https:\/\/www.cpsbc.ca\/files\/pdf\/MMP-Clinical-Practice-Guideline.pdf Accessed 28 Sep 2015."},{"key":"48_CR10","volume-title":"Methadone Maintenance Therapy","author":"Policy Guide","year":"2013","unstructured":"Policy Guide. Methadone Maintenance Therapy. Vancouver, BC: College of Pharmacists of British Columbia; 2013. Report No.: Professional Practice Policy #66."},{"key":"48_CR11","unstructured":"PharmaCare for B.C. Residents. Goverment of British Columbia. 2015. http:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/pharmacare-for-bc-residents . Accessed 28 Sep 2015."},{"key":"48_CR12","unstructured":"Methadone Maintenance Program: Clinical Practice Guidelines. Coll Phys Surg BC; 2014. https:\/\/www.cpsbc.ca\/files\/pdf\/MMP-Clinical-Practice-Guideline.pdf . Accessed 28 Sep 2015."},{"key":"48_CR13","unstructured":"Professional Practice Policy - 71: Delivery of Methadone for Maintenance. College of Pharmacists of British Columbia; 2013. http:\/\/library.bcpharmacists.org\/A-About_Us\/A-2_Governance\/5003-PGP-PPP71.pdf Accessed 28 Sep 2015."},{"key":"48_CR14","unstructured":"Annual Report 2013\u20132014. Coll Phys Surg BC. 2013. https:\/\/www.cpsbc.ca\/files\/pdf\/2013-14-Annual-Report.pdf Accessed 28 Sep 2015."},{"key":"48_CR15","unstructured":"British Columbia Harm Reduction Program. BCCDC. http:\/\/towardtheheart.com . Accessed 28 Sep 2015."},{"key":"48_CR16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.socscimed.2015.04.008","volume":"133","author":"R McNeil","year":"2015","unstructured":"McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, et al. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in vancouver, canada: A qualitative study. Soc Sci Med. 2015;133:168\u201376.","journal-title":"Soc Sci Med."},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0740-5472(99)00008-2","volume":"17","author":"MN Gourevitch","year":"1999","unstructured":"Gourevitch MN, Hartel D, Tenore P, Freeman K, Marion I, Hecht J, et al. Three oral formulations of methadone: A clinical and pharmacodynamic comparison. J Subst Abuse Treat. 1999;17:237\u201341.","journal-title":"J Subst Abuse Treat."},{"issue":"2","key":"48_CR18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2515\/therapie\/2013020","volume":"68","author":"C Eiden","year":"2013","unstructured":"Eiden C, Bertomeu L, Clavel V, Faillie JL, Petit P, Peyriere H. New formulation of methadone for opioid dependence in France: acceptability and diversion\/misuse liability. Therapie. 2013;68(2):107\u201311.","journal-title":"Therapie"},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7517-11-13","volume":"11","author":"M Kuo","year":"2014","unstructured":"Kuo M, Shamsian A, Tzemis D, Buxton JA. A drug use survey among clients of harm reduction sites across British Columbia, Canada, 2012. Harm Reduct J. 2014;11:13.","journal-title":"Harm Reduct J."},{"key":"48_CR20","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.1992.tb02662.x","volume":"87","author":"MD Steels","year":"1992","unstructured":"Steels MD, Hamilton M, McLean PC. The consequences of a change in formulation of methadone prescribed in a drug clinic. Br J Addict. 1992;87:1549\u201354.","journal-title":"Br J Addict."},{"issue":"3","key":"48_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/15622970802416057","volume":"10","author":"M Soyka","year":"2009","unstructured":"Soyka M, Zingg C. Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. World J Biol Psychiatry. 2009;10(3):217\u201324.","journal-title":"World J Biol Psychiatry."},{"key":"48_CR22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2011.01.008","volume":"117","author":"SM Kelly","year":"2011","unstructured":"Kelly SM, O\u2019Grady KE, Mitchell SG, Brown BS, Schwartz RP. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011;117:170\u20135.","journal-title":"Drug Alcohol Depend."},{"key":"48_CR23","first-page":"578","volume":"326","author":"JC Ball","year":"1992","unstructured":"Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. N Engl J Med. 1992;326:578.","journal-title":"N Engl J Med."},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0740-5472(96)00099-2","volume":"13","author":"JS Silver","year":"1997","unstructured":"Silver JS, Shaffer HJ. Change intolerance to shifts in methadone formulation: A preliminary investigation. J Subst Abuse Treat. 1997;13:331\u20139.","journal-title":"J Subst Abuse Treat."},{"key":"48_CR25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0021-9681(87)90187-1","volume":"4","author":"BM Farr","year":"1987","unstructured":"Farr BM, Gwaltney JM. The problems of taste in placebo matching: an evaluation of zinc gluconate for the common cold. J Chronic Dis. 1987;4:875\u20139.","journal-title":"J Chronic Dis."},{"issue":"2","key":"48_CR26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2515\/therapie\/2015015","volume":"70","author":"Q Boucherie","year":"2015","unstructured":"Boucherie Q et al. New methadone formulation in France: results from 5\u00a0years of utilization. Therapie. 2015;70(2):223\u201334.","journal-title":"Therapie."},{"issue":"1\u20133","key":"48_CR27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drugalcdep.2011.10.014","volume":"123","author":"J Trujols","year":"2012","unstructured":"Trujols J et al. Patient satisfaction with methadone maintenance treatment: the relevance of participation in treatment and social functioning. Drug Alcohol Depend. 2012;123(1\u20133):41\u20137.","journal-title":"Drug Alcohol Depend."},{"key":"48_CR28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1192\/pb.27.1.3","volume":"2","author":"T Myton","year":"2003","unstructured":"Myton T. Descriptive study of the effects of altering formulation of prescribed methadone from injectable to oral. Psychiatr Bull. 2003;2:3\u20136.","journal-title":"Psychiatr Bull."},{"key":"48_CR29","first-page":"35","volume":"5","author":"W Ansari El","year":"2004","unstructured":"El Ansari W, Phillips C. The costs and benefits to participants in community partnerships: a paradox? Health Promot Pract. Jan. 2004;5:35\u201348.","journal-title":"Jan"},{"key":"48_CR30","unstructured":"Think before you drink. BC College of Pharmacists; 2014. http:\/\/library.bcpharmacists.org\/A-About_Us\/A-8_Key_Initiatives\/5138-MMT_Patient_Poster_8_5x11.pdf . Accessed 28 Sep 2015."},{"key":"48_CR31","unstructured":"Alberta College of Pharmacists. ODT Guidelines: Medication-Assisted Treatment for Opioid Depednency Guidelines for Pharmacists and Pharmacy Technicians. https:\/\/pharmacists.ab.ca\/system\/files\/ODTGuidelines.pdf . Accessed 28 Sep 2015."},{"key":"48_CR32","unstructured":"Methadose and the Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program. 2014. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/opdp_eo\/notices\/cmmt_faq_pharmacists_20140620.pdf . Accessed 28 Sep 2015."},{"key":"48_CR33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.addbeh.2004.09.004","volume":"30","author":"CJ Strike","year":"2005","unstructured":"Strike CJ, Gnam W, Urbanoski K, Fischer B, Marsh DC, Millson M. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addict Behav. 2005;30:1025\u20138.","journal-title":"Addict Behav."}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-016-0048-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T23:09:40Z","timestamp":1600038580000},"score":1,"resource":{"primary":{"URL":"http:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-016-0048-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1186\/s13011-016-0048-3","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]},"article-number":"3"}}